Summary
Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on January 7, 2013, to announce key strategic goals for its RNAi therapeutics pipeline covering the 2013-2014 period. This announcement provides investors with an updated outlook on the company's development trajectory and potential future milestones. Additionally, the filing provides updated cash guidance, indicating Alnylam expected to close the 2012 fiscal year with approximately $225.0 million in cash, cash equivalents, and marketable securities.
Key Highlights
- 1Alnylam announced key 2013-2014 goals for its RNAi therapeutics pipeline.
- 2The company provided an updated cash guidance for the year ended December 31, 2012.
- 3Alnylam expected to end 2012 with approximately $225.0 million in cash, cash equivalents, and marketable securities.
- 4The information was communicated via a press release furnished as an exhibit to the 8-K.
- 5The filing relates to updates on operational and financial condition, specifically Item 2.02.
Frequently Asked Questions
Alnylam announced key goals for its RNAi therapeutics pipeline for the 2013-2014 period, indicating a focus on advancing its therapeutic candidates.
Alnylam projected that it would end the year 2012 with approximately $225.0 million in cash, cash equivalents, and marketable securities.
The detailed information was released via a press release dated January 6, 2013, which is furnished as Exhibit 99.1 to this Form 8-K filing.